Company AegirBio AB

Equities

AEGIR

SE0014401121

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Stockholm 10:58:02 2024-04-25 am EDT 5-day change 1st Jan Change
0.4955 SEK +0.92% Intraday chart for AegirBio AB -11.36% -57.65%

Business Summary

AegirBio AB is a Sweden-based medicine company focused therapeutic drug monitoring of biologic therapies in the autoimmune, oncology and neurology space. The Company offers tests to monitor and optimize the dosage of biological drugs via its patented technology platform. It aims to provide personalized treatment by tracking drugs levels in individuals. Aegirbio combines core technologies from LifeAssays and Abreos Biosciences. LifeAssays is a diagnostics company based in Sweden, which owns the Magnia Point of Care and Point of Need reader technology. Abreos Biosciences is a California-based biotech, which is a developer of the Veritope chemistry platform for detecting levels of biologic drugs in patient samples.

Number of employees: 13

Sales per Business

SEK in Million2021Weight2022Weight Delta
Covid-19 Saliva Test Viraspec
82.2 %
13 95.9 % 1 82.2 % -88.99%
Custom Veritope Development Project
17.8 %
- - 0 17.8 % -

Sales per region

SEK in Million2021Weight2022Weight Delta
Sweden
82.2 %
9 69.7 % 1 82.2 % -84.86%
United States
17.8 %
-- 0 17.8 % -

Managers

Managers TitleAgeSince
Chief Executive Officer - 23-06-14
Director of Finance/CFO - 23-04-18
Chief Operating Officer - Oct. 31

Members of the board

Members of the board TitleAgeSince
Director/Board Member 72 20-01-31
Chairman 67 19-11-30
Director/Board Member 54 22-05-31
Director/Board Member 49 20-04-30
Director/Board Member 57 22-05-31

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 25,876,872 23,180,538 ( 89.58 %) 0 89.58 %

Company contact information

AegirBio AB

Scheelevägen 27

223 63, Lund

+46 4 62 86 54 00

http://www.aegirbio.com
address AegirBio AB(AEGIR)